Retrospective analysis identifies vascular and biochemical risk factors in patients with diabetic foot ulcers, indicating critical management strategies.
Background: Diabetic foot ulcer (DFU) is a major complication of diabetes mellitus and remains a significant contributor to morbidity, limb amputation, and mortality. Although substantial efforts have been made in prevention and treatment, ulcer recurrence continues to pose a critical clinical challenge. Understanding the multifactorial nature of recurrence and identifying reliable predictors are essential for improving long-term outcomes. Methods: This retrospective case-control study included 230 patients diagnosed with DFU and treated between October 2020 and January 2025. Patients were stratified into recurrence (n = 103) and non-recurrence (n = 127) groups based on ulcer outcomes within a two-year follow-up period. Clinical, demographic, foot-related, comorbid, and biochemical variables were extracted from medical records and follow-up assessments. Statistical analyses included univariate tests and binary logistic regression to determine independent predictors of DFU recurrence. Results: Significant differences were found between groups across multiple domains. Patients with recurrence had lower body mass index (BMI, p = 0.045) and a higher prevalence of poor financial status (p = 0.021). Foot-specific characteristics, including higher Wagner grade, prolonged ulcer duration, prior amputations, and plantar ulcer location, were all significantly associated with recurrence (p < 0.05). Laboratory findings revealed elevated C-reactive protein and decreased serum albumin levels in the recurrence group (p < 0.001). Notably, lower total bilirubin (TBIL) levels were observed in recurrent cases and remained an independent protective factor (OR = 0.898, p = 0.041). Multivariate analysis identified diabetic peripheral neuropathy (DPN), peripheral arterial disease (PAD), prior amputations, and plantar ulceration as significant predictors of recurrence. Conclusion: DFU recurrence is driven by a complex interplay of vascular, neurological, anatomical, and biochemical factors. The identification of total bilirubin as a potential protective biomarker highlights new avenues for risk stratification. These findings underscore the importance of a comprehensive, multidisciplinary approach in DFU management to reduce recurrence and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Ruangsak et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: